Carrie Smith Cox, Executive Chair of Organon & Co. ($OGN), made two open market purchases of company shares in the last year, totaling about $602,000. Her most recent buy occurred on November 12, 2025. Among nearly 5,000 insiders tracking open market buys, her total ranks 734th, below the average of $1.46 million across 3.29 transactions per insider. She reported no open market sales in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 27, 2026 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | M | Restricted Stock Units | 6336 | $0.00 | 0.0000 | 175,400,000 | 100.00% | 0.00% |
| March 27, 2026 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | M | Common Stock | 6336 | $0.00 | 11,484.0000 | 175,400,000 | 123.08% | 0.00% |
| Jan. 29, 2026 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | NQ Stock Option (Right to Buy) | 1860 | $0.00 | 1,860.0000 | 913,000,000 | 9999.99% | 0.00% |
| Jan. 29, 2026 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | Common Stock | 525 | $0.00 | 37,626.0000 | 913,000,000 | 1.42% | 0.00% |
| Nov. 12, 2025 | Organon & Co. | $OGN | COX CARRIE SMITH | Executive Chair | P | Common Stock | 65400 | $7.67 | 77,869.0000 | 260,653,000 | 524.50% | 0.03% |
| June 13, 2025 | Organon & Co. | $OGN | COX CARRIE SMITH | Director | A | Phantom Stock | 23904 | $10.04 | 74,029.7690 | 259,152,000 | 47.69% | 0.01% |
| May 13, 2025 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | M | Restricted Stock Units | 5148 | $0.00 | 0.0000 | 173,700,000 | 100.00% | 0.00% |
| May 14, 2025 | Organon & Co. | $OGN | COX CARRIE SMITH | Director | P | Common Stock | 12469 | $8.07 | 12,469.0000 | 259,152,000 | 9999.99% | 0.00% |
| May 13, 2025 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | M | Common Stock | 5148 | $0.00 | 5,148.0000 | 173,700,000 | 9999.99% | 0.00% |
| April 30, 2025 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | A | Restricted Stock Units | 4916 | $0.00 | 4,916.0000 | 173,700,000 | 9999.99% | 0.00% |
| Jan. 27, 2025 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | Common Stock | 614 | $0.00 | 37,101.0000 | 919,000,000 | 1.68% | 0.00% |
| Jan. 27, 2025 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | NQ Stock Option (Right to Buy) | 2551 | $0.00 | 2,551.0000 | 919,000,000 | 9999.99% | 0.00% |
| Jan. 2, 2025 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | A | Common Stock | 2600 | $0.00 | 15,629.0000 | 25,767,369 | 19.96% | 0.01% |
| Jan. 2, 2025 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | A | Stock Option (Right to Buy) | 8000 | $0.00 | 16,266.0000 | 25,767,369 | 96.78% | 0.03% |
| June 7, 2024 | Organon & Co. | $OGN | COX CARRIE SMITH | Director | A | Phantom Stock | 9639 | $20.75 | 47,059.8590 | 256,270,000 | 25.76% | 0.00% |
| May 13, 2024 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | A | Restricted Stock Units | 6336 | $0.00 | 11,484.0000 | 172,700,000 | 123.08% | 0.00% |
| May 13, 2024 | Solventum Corp | $SOLV | COX CARRIE SMITH | Director | A | Restricted Stock Units | 5148 | $0.00 | 5,148.0000 | 172,700,000 | 9999.99% | 0.00% |
| Jan. 25, 2024 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | Common Stock | 686 | $0.00 | 36,487.0000 | 916,000,000 | 1.92% | 0.00% |
| Jan. 25, 2024 | TEXAS INSTRUMENTS INC | $TXN | COX CARRIE SMITH | Director | A | NQ Stock Option (Right to Buy) | 3066 | $0.00 | 3,066.0000 | 916,000,000 | 9999.99% | 0.00% |
| Jan. 2, 2024 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | A | Stock Option (Right to Buy) | 248000 | $0.00 | 248,000.0000 | 5,397,597 | 9999.99% | 4.59% |
| Jan. 2, 2024 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | A | Common Stock | 178000 | $0.00 | 390,881.0000 | 5,397,597 | 83.61% | 3.30% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | D | Stock Option (Right to Buy) | 60000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 1.18% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | D | Stock Option (Right to Buy) | 107500 | $0.93 | 0.0000 | 5,101,459 | 100.00% | 2.11% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | D | Stock Option (Right to Buy) | 30000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 0.59% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | D | Stock Option (Right to Buy) | 20000 | $0.74 | 0.0000 | 5,101,459 | 100.00% | 0.39% |
| Nov. 13, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | D | Stock Option (Right to Buy) | 60000 | $0.00 | 0.0000 | 5,101,459 | 100.00% | 1.18% |
| June 9, 2023 | Organon & Co. | $OGN | COX CARRIE SMITH | Director | A | Phantom Stock | 10086 | $19.83 | 35,232.0000 | 255,169,000 | 40.11% | 0.00% |
| Jan. 2, 2023 | Cartesian Therapeutics, Inc. | $RNAC | COX CARRIE SMITH | Director | A | Stock Option (Right to Buy) | 107500 | $0.00 | 107,500.0000 | 5,101,459 | 9999.99% | 2.11% |